Longacting cabotegravir and rilpivirine dosed every 2 months in adults with HIV1 infection ATLAS2M 48week results a randomised multicentre openlabel phase 3b noninferiority study
Files
Date
Authors
Hans Jaeger
Edgar T Overton
Gary Richmond
Giuliano Rizzardini
Jaime Federico Andrade-Villanueva
E et al
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Citation
WOS